FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083070003> ?p ?o ?g. }

• W2083070003 endingPage "370" @default.
• W2083070003 startingPage "365" @default.
• W2083070003 abstract "Purpose: Rituximab is a monoclonal antibody targetting the CD20 antigen with the ability to increase overall remission (OR) in B-cell non-Hodgkin’s lymphoma (B-NHL). A systematic review and meta-analysis were conducted to determine the risk of the most clinically relevant severe and fatal adverse events (AEs) associated with the use of rituximab in the treatment of B-NHL.Patients and methods: We included phase III clinical trials that used chemotherapy in combination with rituximab or chemotherapy alone as for B-NHL. Statistical analyses were conducted to calculate summary risk ratio (RR) of the relevant severe and fatal AEs related with rituximab.Results: Eight randomised controlled clinical trials were included in this meta-analysis. Summary RR obtained showed no statistically significant rituximab-associated increased risk in 13 severe adverse events (SAEs) (infection, fever, anaemia, thrombocytopaenia, granulocytopenia, liver toxicity, cardiac toxicity, neurologic toxicity, lung toxicity, mucositis, nausea/vomiting, diarrhoea, alopecia) except leukocytopenia (36.4% versus 31%; RR = 1.13; 95%CI, 1.01–1.27; P = 0.03). The incidences of fatal AEs showed noteworthy difference between rituximab group and control group (RR = 1.45; 95% CI, 1.04–2.02; P = 0.03).Conclusion: This meta-analysis indicates that there was no proof of statistically higher incidence of most SAEs in rituximab containing group compared with chemotherapy alone. However, fatal infections were more frequently observed in patients who received rituximab. Considering the low-incidence infection-induced death during the treatment period, the effects of rituximab on infections need further investigation." @default.
• W2083070003 created "2016-06-24" @default.
• W2083070003 creator A5024677474 @default.
• W2083070003 creator A5058253422 @default.
• W2083070003 creator A5075378390 @default.
• W2083070003 date "2015-04-15" @default.
• W2083070003 modified "2023-10-18" @default.
• W2083070003 title "Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin’s lymphoma (B-NHL) chemotherapy: a meta-analysis" @default.
• W2083070003 cites W1158258141 @default.
• W2083070003 cites W1966831995 @default.
• W2083070003 cites W1975736815 @default.
• W2083070003 cites W1977206110 @default.
• W2083070003 cites W1983249596 @default.
• W2083070003 cites W1986215651 @default.
• W2083070003 cites W1994630947 @default.
• W2083070003 cites W2027043998 @default.
• W2083070003 cites W2030437282 @default.
• W2083070003 cites W2035451502 @default.
• W2083070003 cites W2043103956 @default.
• W2083070003 cites W2048787440 @default.
• W2083070003 cites W2057262661 @default.
• W2083070003 cites W2058015212 @default.
• W2083070003 cites W2064212538 @default.
• W2083070003 cites W2070795385 @default.
• W2083070003 cites W2072268910 @default.
• W2083070003 cites W2079365532 @default.
• W2083070003 cites W2081735553 @default.
• W2083070003 cites W2097145287 @default.
• W2083070003 cites W2105611145 @default.
• W2083070003 cites W2128713289 @default.
• W2083070003 cites W2133902485 @default.
• W2083070003 cites W2139942643 @default.
• W2083070003 cites W2151177887 @default.
• W2083070003 cites W2153665789 @default.
• W2083070003 cites W2154643481 @default.
• W2083070003 cites W2156015715 @default.
• W2083070003 cites W2159982513 @default.
• W2083070003 cites W2160305510 @default.
• W2083070003 cites W2161004701 @default.
• W2083070003 cites W2163790170 @default.
• W2083070003 cites W2171356556 @default.
• W2083070003 cites W2402735797 @default.
• W2083070003 cites W4294215472 @default.
• W2083070003 doi "https://doi.org/10.1179/1973947815y.0000000025" @default.
• W2083070003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25872413" @default.
• W2083070003 hasPublicationYear "2015" @default.
• W2083070003 type Work @default.
• W2083070003 sameAs 2083070003 @default.
• W2083070003 citedByCount "16" @default.
• W2083070003 countsByYear W20830700032015 @default.
• W2083070003 countsByYear W20830700032016 @default.
• W2083070003 countsByYear W20830700032017 @default.
• W2083070003 countsByYear W20830700032018 @default.
• W2083070003 countsByYear W20830700032019 @default.
• W2083070003 countsByYear W20830700032020 @default.
• W2083070003 countsByYear W20830700032021 @default.
• W2083070003 countsByYear W20830700032022 @default.
• W2083070003 countsByYear W20830700032023 @default.
• W2083070003 crossrefType "journal-article" @default.
• W2083070003 hasAuthorship W2083070003A5024677474 @default.
• W2083070003 hasAuthorship W2083070003A5058253422 @default.
• W2083070003 hasAuthorship W2083070003A5075378390 @default.
• W2083070003 hasConcept C126322002 @default.
• W2083070003 hasConcept C141071460 @default.
• W2083070003 hasConcept C197934379 @default.
• W2083070003 hasConcept C2776694085 @default.
• W2083070003 hasConcept C2778496288 @default.
• W2083070003 hasConcept C2779338263 @default.
• W2083070003 hasConcept C2780580376 @default.
• W2083070003 hasConcept C2780653079 @default.
• W2083070003 hasConcept C2780852908 @default.
• W2083070003 hasConcept C2909463153 @default.
• W2083070003 hasConcept C71924100 @default.
• W2083070003 hasConcept C90924648 @default.
• W2083070003 hasConceptScore W2083070003C126322002 @default.
• W2083070003 hasConceptScore W2083070003C141071460 @default.
• W2083070003 hasConceptScore W2083070003C197934379 @default.
• W2083070003 hasConceptScore W2083070003C2776694085 @default.
• W2083070003 hasConceptScore W2083070003C2778496288 @default.
• W2083070003 hasConceptScore W2083070003C2779338263 @default.
• W2083070003 hasConceptScore W2083070003C2780580376 @default.
• W2083070003 hasConceptScore W2083070003C2780653079 @default.
• W2083070003 hasConceptScore W2083070003C2780852908 @default.
• W2083070003 hasConceptScore W2083070003C2909463153 @default.
• W2083070003 hasConceptScore W2083070003C71924100 @default.
• W2083070003 hasConceptScore W2083070003C90924648 @default.
• W2083070003 hasIssue "6" @default.
• W2083070003 hasLocation W20830700031 @default.
• W2083070003 hasLocation W20830700032 @default.
• W2083070003 hasOpenAccess W2083070003 @default.
• W2083070003 hasPrimaryLocation W20830700031 @default.
• W2083070003 hasRelatedWork W1996898072 @default.
• W2083070003 hasRelatedWork W2081557631 @default.
• W2083070003 hasRelatedWork W2111792237 @default.
• W2083070003 hasRelatedWork W2262648772 @default.
• W2083070003 hasRelatedWork W2368337335 @default.
• W2083070003 hasRelatedWork W2375265431 @default.
• W2083070003 hasRelatedWork W2377198612 @default.

• next